Use of Monoclonal Antibodies (mAbs) Under an Emergency Use Authorization (EUA) in Patients with COVID-19 Diagnosis: An Updated Descriptive Analysis

    Basic Details
    Date Posted
    Wednesday, August 24, 2022
    Status
    Complete
    Medical Product
    bamlanivimab
    bamlanivimab etesevimab
    casirivimab imdevimab
    Health Outcome(s)
    utilization
    Description

    In this report, we examined counts of individuals using the monoclonal antibodies (mAbs) under an Emergency Use Authorization (EUA) in the Rapid Coronavirus-19 Disease (COVID-19) Sentinel Distributed Database (SDD).

    The study period includes data from November 1, 2020 to June 30, 2021. We distributed this request to five Sentinel Data Partners on July, 28, 2021.